Sarepta Therapeutics Inc
$ 22.12
-0.90%
26 Dec - close price
- Market Cap 2,317,893,000 USD
- Current Price $ 22.12
- High / Low $ 22.41 / 21.86
- Stock P/E N/A
- Book Value 12.60
- EPS -2.83
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.21 %
- 52 Week High 129.84
- 52 Week Low 10.41
About
Sarepta Therapeutics, Inc. is a leading biopharmaceutical company located in Cambridge, Massachusetts, specializing in RNA-targeted and gene therapies for rare genetic disorders, with a notable focus on Duchenne muscular dystrophy (DMD). The company boasts a robust pipeline of innovative therapies aimed at addressing critical unmet medical needs, positioning itself at the forefront of genetic medicine. Leveraging advanced scientific expertise and pioneering technologies, Sarepta is committed to transforming treatment paradigms and enhancing patient outcomes in the biopharmaceutical industry.
Analyst Target Price
$20.61
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-03 | 2025-08-06 | 2025-04-29 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-01 | 2024-02-28 | 2023-11-01 | 2023-08-02 | 2023-05-02 | 2023-02-28 |
| Reported EPS | -0.13 | 2.02 | -3.42 | 1.9 | 0.34 | 0.07 | 0.37 | 0.47 | -0.46 | -0.27 | -5.86 | -1.24 |
| Estimated EPS | -0.6985 | 0.7 | -0.6494 | 2.0603 | -0.13 | 0.01 | -0.07 | 0.01 | -1.23 | -1.78 | -1.38 | -1.35 |
| Surprise | 0.5685 | 1.32 | -2.7706 | -0.1603 | 0.47 | 0.06 | 0.44 | 0.46 | 0.77 | 1.51 | -4.48 | 0.11 |
| Surprise Percentage | 81.3887% | 188.5714% | -426.64% | -7.7804% | 361.5385% | 600% | 628.5714% | 4600% | 62.6016% | 84.8315% | -324.6377% | 8.1481% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRPT
2025-12-27 14:09:49
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sarepta Therapeutics, Inc. (SRPT) after the company announced on November 3, 2025, that its ESSENCE trial for two gene therapies did not meet its primary endpoint, causing a significant drop in its stock price. The firm is encouraging investors who purchased Sarepta securities to learn more about the investigation and potentially participate. This legal action aims to recover investor capital and ensure corporate accountability.
2025-12-26 14:09:34
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sarepta Therapeutics, Inc. (SRPT) following a significant drop in its stock price. This decline occurred after Sarepta announced on November 3, 2025, that its late-stage ESSENCE trial for two Duchenne muscular dystrophy gene therapies, AMONDYS 45 and VYONDYS 5, did not meet its primary endpoint, causing a 33.74% share price fall. The firm is encouraging investors who purchased Sarepta securities to join the investigation.
2025-12-26 11:00:00
Bronstein, Gewirtz & Grossman, LLC is investigating Sarepta Therapeutics, Inc. (SRPT) after the company disclosed that its ESSENCE trial for two Duchenne muscular dystrophy gene therapies did not meet its primary endpoint, causing a significant stock price drop. The firm encourages investors who purchased Sarepta securities to join the investigation. This aims to recover investor capital and ensure corporate accountability.
2025-12-26 09:08:17
Assenagon Asset Management S.A. significantly reduced its stake in Sarepta Therapeutics by selling 838,457 shares, leaving them with 29,482 shares valued at approximately $568,000. Despite a brutal year for Sarepta with a Q3 EPS miss and a 14.5% YoY revenue decline, analysts maintain a "Hold" consensus rating with a target price of $33.68, suggesting a potential 179% upside. Other institutional investors like Ancora Advisors LLC, Banque Transatlantique SA, and AlphaQuest LLC have also adjusted their positions, with insiders owning 7.60% of the company's stock.
2025-12-25 15:08:18
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Sarepta Therapeutics, Inc. (SRPT) on behalf of investors. This investigation follows Sarepta's disclosure on November 3, 2025, that its ESSENCE trial for two Duchenne muscular dystrophy gene therapies did not meet its primary endpoint, causing a significant drop in their stock price. The firm encourages affected investors to connect with them for more information.
2025-12-23 17:10:11
Sarepta Therapeutics (SRPT) saw its stock price rise by 3.5% with extremely light trading volume. Analyst sentiment is mixed, with an average "Hold" rating and a price target of $33.68. The COO recently sold 13,187 shares, representing a 6.39% decrease in their ownership.
